Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2018 08:00 ET | Source: Immunomedics, Inc.

Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. Food and Drug Administration

MORRIS PLAINS, N.J., May 21, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a science-based and innovation-focused biopharmaceutical company committed...
May 16, 2018 17:01 ET | Source: Immunomedics, Inc.

Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast Cancer

Sacituzumab Govitecan Produced Overall Response Rate of 31 Percent in Patients Post Endocrine Treatment with a Manageable Safety Profile Full Data will be Reported in Oral Presentation at 2018...
May 09, 2018 16:00 ET | Source: Immunomedics, Inc.

Immunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate Update

Biologics License Application (BLA) Remains on Track to be Submitted by the End of May 2018 Leadership Team Expanded with Appointment of Dr. Robert Iannone, Head of Research & Development and...
May 02, 2018 08:00 ET | Source: Immunomedics, Inc.

Immunomedics to Report Third Quarter Fiscal 2018 Results and Host Conference Call and Webcast on May 9, 2018

MORRIS PLAINS, N.J., May 02, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that it will host a conference call on Wednesday, May 9,...
April 25, 2018 12:15 ET | Source: Immunomedics, Inc.

Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (mBC) at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

MORRIS PLAINS, N.J., April 25, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leader in the field of antibody-drug conjugates (ADCs), today announced...
April 09, 2018 08:00 ET | Source: Immunomedics, Inc.

Immunomedics Appoints Dr. Robert Iannone Head of Research & Development and Chief Medical Officer

MORRIS PLAINS, N.J., April 09, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leader in the field of antibody-drug conjugates (ADCs), today announced...
March 05, 2018 08:00 ET | Source: Immunomedics, Inc.

Immunomedics to Present at Cowen and Company 38th Annual Health Care Conference

MORRIS PLANS, N.J., March 05, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that Michael Pehl, President and Chief Executive Officer,...
February 15, 2018 08:00 ET | Source: Immunomedics, Inc.

Immunomedics to Participate in RBC Capital Markets 2018 Global Healthcare Conference

MORRIS PLAINS, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that Michael Pehl, President and Chief Executive Officer,...
February 08, 2018 16:15 ET | Source: Immunomedics, Inc.

Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update

Presented Compelling Results with Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer (mTNBC) at San Antonio Breast Cancer Symposium Secured $250 Million Funding to Support Company’s...
February 06, 2018 08:00 ET | Source: Immunomedics, Inc.

Immunomedics to Report Second Quarter Fiscal 2018 Results and Host Conference Call and Webcast on February 8, 2018

MORRIS PLAINS, N.J., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that it will host a conference call on Thursday, February 8,...